Company Overview

Nexalin Technology, Inc. is a U.S.-based medical technology company focused on non-invasive neurostimulation technologies intended to address mental health and neurological conditions. The company operates within the medical device and digital health industries, with a primary emphasis on therapies targeting anxiety, insomnia, depression, substance use disorders, and related behavioral health conditions. Its core commercial offering is the Gen-2 Neurostimulation Device, which uses low-frequency electrical stimulation designed to influence brainwave activity without pharmaceuticals or invasive procedures.

The company’s business model centers on device sales, treatment sessions, clinical expansion initiatives, and intellectual property development related to neurostimulation therapy. Nexalin has positioned itself within the growing neurotechnology and mental health treatment market by promoting non-drug therapeutic alternatives for patients and healthcare providers. Public filings and company disclosures indicate that the business evolved from earlier technology and healthcare ventures before focusing primarily on neurostimulation-based medical technologies. Data regarding certain early-stage historical corporate transitions is limited across public sources and partially inconsistent in secondary reporting.

Business Operations

Nexalin conducts operations primarily through its neurostimulation technology platform and related healthcare commercialization activities. The company’s principal business unit is its neurostimulation device operation, including the development, regulatory advancement, manufacturing coordination, and commercialization of its proprietary treatment systems. Revenue generation has historically been tied to device placements, treatment-related services, and expansion of clinical partnerships. Public disclosures indicate that the company has also pursued international distribution relationships and healthcare provider network expansion.

The company’s operations are concentrated largely in the United States, though Nexalin has disclosed efforts to broaden its international reach through distribution agreements and strategic healthcare collaborations in select overseas markets. Key assets include proprietary neurostimulation technologies, patent-related intellectual property, and clinical research initiatives associated with neurological and behavioral health applications. Public filings reference collaborations with healthcare practitioners, clinics, and distributors; however, comprehensive disclosure regarding the financial scale or operational materiality of certain partnerships remains limited in publicly available records.

Strategic Position & Investments

Nexalin’s strategic direction has focused on expanding the commercial adoption of non-invasive neurostimulation therapies while pursuing additional regulatory pathways and clinical validation studies. Growth initiatives have included the development of next-generation neurostimulation systems, increased treatment accessibility, and broader clinical application research involving mental health and neurological conditions. The company has also emphasized intellectual property development and international commercialization opportunities as part of its long-term growth strategy.

Public disclosures indicate investments in research and development related to advanced stimulation technologies and potential new therapeutic indications. Nexalin has highlighted interest in emerging healthcare sectors involving neuromodulation, behavioral health technology, and non-pharmaceutical treatment alternatives. The company remains relatively small compared with larger established medical device firms, and several strategic initiatives appear to be in developmental or early commercialization stages. Information regarding large-scale acquisitions or extensive subsidiary holdings is limited based on available public sources.

Geographic Footprint

Nexalin Technology, Inc. is headquartered in the United States, with operations centered primarily in the domestic healthcare and medical device market. The company has pursued broader international exposure through distributor relationships and commercialization discussions in regions including parts of Asia, the Middle East, and other international healthcare markets referenced in company disclosures.

While Nexalin’s operational scale remains significantly concentrated in the U.S., public filings and investor materials indicate efforts to expand its global market presence through international partnerships and regulatory engagement. The company’s international operational influence appears to remain in an expansion phase rather than a fully established multinational footprint. Data regarding the exact scale of foreign revenue contribution is inconclusive based on available public sources.

Leadership & Governance

Nexalin Technology, Inc. is led by an executive team focused on commercialization of neurostimulation technologies and expansion within the behavioral health treatment sector. Corporate governance and strategic messaging have emphasized innovation in non-invasive therapy solutions, regulatory progression, and broader healthcare accessibility for mental health treatment alternatives. Public company disclosures indicate a leadership strategy centered on clinical validation, market adoption, and long-term intellectual property development.

Key executives include:

• Mark White – Chief Executive Officer
• Richard J. Cotroneo – Chief Financial Officer
• John McCracken – President
• Robert J. DeLuccia – Chairman of the Board

Leadership and governance information has been verified through public company filings, investor materials, and exchange disclosures. Certain executive role timelines and historical board compositions may vary slightly across reporting periods due to leadership transitions and filing dates.